D. Western Therapeutics Institute (DWTI) (4576 JP) - Q3 Follow-Up
SUMMARY
- For H-1337, DWTI completed dosing of subjects in the Phase IIb clinical trial in August, and top-line data was announced on November 18.
- All three doses of H- 1337 achieved clinically and statistically significant decreases of up to 30% in intraocular pressure (IOP) which was in the same range as the positive control, existing beta-blocker timolol (p <0.001), and DWTI expects H-1337 will proceed to Phase 3 study based on these results (see P10 for details).
- For DWR-2206, DWTI submitted a notification of clinical trial plan for domestic Phase II clinical trials to the PMDA in March, and the transplant for the first subject was performed in July.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x